Clinical Trials Logo

Clinical Trial Summary

Pulmonary Embolism (PE) is a frequent disease, the third cause of cardiovascular death after stroke and myocardial infarction. According to European guidelines of European Society of Cardiology (ESC) and of European Respiratory Society (ERS), the prognostic stratification of PE severity is mandatory as soon as PE is diagnosed. This stratification includes the hemodynamic status, and specific tools : the assessment of the sPESI score, and the evaluation of PE's impact on right ventricle (RV) : increased biomarkers (troponin, BNP) and right ventricle/left ventricle (RV/LV) ratio.

the RV/LV ration may be evaluated ideally by transthoracic echo (TTE), or by CT scan. Unfortunately, only 10% of patients with PE are evaluated with TTE by a cardiologist in the initial time of PE diagnosis. Hence, the CT scan is the most frequent way to assess RV/LV ratio. However, CT is not possible for all patients (patients with contra-indication) or may have difficulties to provide a clear assessment because of technical issues.

Then, there is a need for morphological evaluation of RV as soon as PE is diagnosed, in every clinical setting. The improvement in technologies allowed the development of clinical echography (CE) in emergency departments.

CE is already available, non-invasive, less expansive, and may be a good way to assess RV/LV ratio in patients with PE diagnosed in emergency departments.

The investigators propose a prospective, multicenter study to assess the sensitivity of CE in patients with PE, compared to CT scan to detect RV/LV ≥0.9.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03366519
Study type Observational
Source Centre Hospitalier Universitaire de Saint Etienne
Contact
Status Withdrawn
Phase
Start date November 2018
Completion date January 2019

See also
  Status Clinical Trial Phase
Completed NCT01258140 - Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography N/A
Completed NCT05770232 - Retrospectively Analyze the Risk Factors of VTE in 5774 Patients With Thoracic Trauma From 33 Hospitals in China, and Established a Risk Prediction Model
Completed NCT00981409 - The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients Phase 3
Recruiting NCT04731558 - Pre- vs Postoperative Thromboprophylaxis for Liver Resection Phase 4
Terminated NCT05172115 - Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE Phase 3